Assignee
KEROS THERAPEUTICS INC
US·17 granted patents·17 pending applications·54 citations·filing 2017–2025
Top patents by PatentIndex Score
34 records- 0196US11717558B2Nucleic acid molecules encoding activin receptor type IIA variantsKEROS THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·6 cites·12 claims
- 0295US12350313B2Activin receptor type IIa variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2023·Granted Jul 8, 2025·3 cites·20 claims
- 0395US11884715B2Activin receptor type IIB variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·6 cites·14 claims
- 0495US11090361B2Activin receptor type IIa variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2017·Granted Aug 17, 2021·11 cites·10 claims
- 0595US11013785B2Activin receptor type IIA variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2017·Granted May 25, 2021·12 cites·20 claims
- 0694US12269858B2Activin receptor type IIB variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2024·Granted Apr 8, 2025·2 cites·13 claims
- 0792US11484573B2Activin receptor type IIa variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2018·Granted Nov 1, 2022·8 cites·23 claims
- 0891US12364737B2Activin receptor type IIA variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2020·Granted Jul 22, 2025·3 cites·11 claims
- 0988US12071438B2Crystal forms of an ALK2 inhibitorKEROS THERAPEUTICS INC·Filed 2021·Granted Aug 27, 2024·2 cites·17 claims
- 1084US12582700B2Activin receptor type IIA variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2025·Granted Mar 24, 2026·0 cites·6 claims
- 1181US12404313B2GDNF fusion polypeptides and methods of use thereofKEROS THERAPEUTICS INC·Filed 2024·Granted Sep 2, 2025·0 cites·15 claims
- 1279US2025312415A1Activin receptor type iia variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1378US2026022150A1Gdnf fusion polypeptides and methods of use thereofKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1475US11912750B2GDNF fusion polypeptides and methods of use thereofKEROS THERAPEUTICS INC·Filed 2017·Granted Feb 27, 2024·1 cites·19 claims
- 1571US2025206799A1Activin receptor type iib variants and methods of use thereofKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1668US2026098078A1Activin receptor type ii chimeras and methods of use thereofKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1767US2025270333A1Alk2 antibodies and methods of use thereofKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1864US2026078161A1Methods of using activin receptor type ii variantsKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1963US12331124B2ALK2 antibodies and methods of use thereofKEROS THERAPEUTICS INC·Filed 2021·Granted Jun 17, 2025·0 cites·13 claims
- 2061US12522646B2Activin receptor type II chimeras and methods of use thereofKEROS THERAPEUTICS INC·Filed 2022·Granted Jan 13, 2026·0 cites·7 claims
- 2161US2024252631A1Methods of using activin receptor type ii signaling inhibitorsKEROS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2261US2023348565A1Methods of using activin receptor type ii variantsKEROS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2358US2024218061A1Methods of using activin receptor type ii signaling inhibitorsKEROS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2457US12440539B2Methods of using activin receptor type IIB variantsKEROS THERAPEUTICS INC·Filed 2022·Granted Oct 14, 2025·0 cites·10 claims
- 2557US2023372390A1Methods of treating lymphopeniaKEROS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2657US2023398118A1Methods of treating cardiovascular-related diseaseKEROS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2756US2023265162A1Methods of using activin receptor type iia variantsKEROS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2855US12458693B2Methods of treating iron overload with a BMP inhibitorKEROS THERAPEUTICS INC·Filed 2023·Granted Nov 4, 2025·0 cites·15 claims
- 2955US2025034148A1Methods of using alk2 inhibitorsKEROS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3053US2025282877A1Methods of using alk2 and alk3 antibodiesKEROS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3152US2024228583A1Activin receptor type ii chimeras and methods of use thereofKEROS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3250US12508262B2Methods of using ALK2 inhibitorsKEROS THERAPEUTICS INC·Filed 2021·Granted Dec 30, 2025·0 cites·2 claims
- 3348US2025270287A1Activin receptor type ii chimeras and methods of use thereofKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3448US2025188148A1Methods of administering an activin receptor type iib variantKEROS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when KEROS THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →